No coin nor oath required. For personal study only.
Materia Inc announced the licensing of its metathesis platform to Aileron Therapeutics, an emerging biopharmaceutical company, for use in the discovery and development of peptide therapeutics directed at intracellular protein-protein interaction targets. As consideration for the licence, Materia will receive licence fees, milestone payments, and royalties. Metathesis catalysts enable the formation and manipulation of carbon-carbon bonds in the synthesis of entirely new biopharmaceutical products with superior properties as well as in the development of new, more efficient and low cost production processes for existing products.
๐ SIMILAR VOLUMES
The company is using nanomaterial catalysts to make biodiesel production cheaper